Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.

Blood cancer discovery - 8 Jan 2024

Falini Brunangelo, Dillon Richard

Abstract excerpt

NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. NPM1-mutated AML is recognizable by molecular techniques and immunohistochemistry, which, when combined, can solve difficult diagnostic problems (including identification of myeloid sarcoma and NPM1 mutations outside exon 12). According to updated 2022 European LeukemiaNet (ELN) guidelines, determining the mutational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nuclear Proteins

Share to Nuclear Structure and Function

Share to Nucleophosmin

Share to Retinoids in leukemia and cellular processes

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 37917833
DOI: 10.1158/2643-3230.BCD-23-0144
PMCID: PMC10772525

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.PMID 37917833Read ↗

How I diagnose and treat NPM1 -mutated AMLSemantic proximity Read ↗

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?Semantic proximity Read ↗

Correlation of NPM1 immunohistochemistry with mutation subtypes, clinicopathologic variables and molecular testing in AML with NPM1 mutation.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Biological and clinical consequences of NPM1 mutations in AML.Semantic proximity Read ↗

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.Semantic proximity Read ↗

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemiaSemantic proximity Read ↗

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.Semantic proximity Read ↗

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AMLSemantic proximity Read ↗

Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.Semantic proximity Read ↗

Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.